Falling rupee to boost pharma top lines, margins in Q2: India Ratings

However, drug firms focussed on domestic market would post muted growth in Q2FY19 on a year-on-year basis

Riding on the depreciation of the Indian currency vis-a-vis the US dollar, analysts expect the pharmaceutical sector to report higher margins in the second quarter of the fiscal. 

In a recent report India Ratings and Research highlighted that while pricing pressure in regulated markets, input cost inflation and increased competition continue to be the key concerns for the sector for the remaining FY19, the rupee will continue to weaken against the dollar and thus support the top line growth of pharma firms. This would also safeguard them from margin pressure, the market research firm noted.

The report also noted that majority of